Stock Frenzy After Surprisingly Positive EMDAC Vote on Qnexa

Shares of Vivus Inc. surged 77.5 percent Thursday following an overwhelmingly positive vote by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for its weight loss candidate Qnexa (phentermine/topiramate). (See BioWorld Today, Feb. 23, 2012.)